Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
bcl-x Antibody (SPM337), Novus Biologicals™

Mouse Monoclonal Antibody
Supplier: Novus Biologicals NBP2444160.02MG
Description
Ensure accurate, reproducible results in Western Blot, Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence
Bcl-xL Monoclonal specifically detects Bcl-xL in Human, Mouse, Rat, Porcine samples. It is validated for Western Blot, Flow Cytometry, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin, Immunofluorescence.Specifications
Bcl-xL | |
Monoclonal | |
0.2mg/mL | |
Western Blot 0.5 - 1.0 ug/ml, Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, Immunohistochemistry-Paraffin 0.5 - 1.0 ug/ml, Immunofluorescence 0.5 - 1.0 ug/ml | |
Q07817 | |
BCL2L1 | |
A synthetic peptide, aa 3-14 (Cys-QSNRELVVDFLS) of human Bcl-X protein. | |
Protein A or G purified | |
RUO | |
Primary | |
Recognizes a protein of 27kDa, identified as the Bcl-X protein. This MAb shows no cross-reaction with Bcl-2 or Bax protein. Bcl-X has two isoforms, Bcl-XL (long), a 241 amino acid protein which suppresses cell death. And Bcl-XS (short), a 178 amino acid protein lacking a 63 amino acid domain which functions as a dominant inhibitor of Bcl-2. This MAb reacts with both Bcl-XS and Bcl-XL proteins. | |
Store at 4C. | |
IgG2a |
Western Blot, Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence | |
SPM337 | |
Unconjugated | |
10mM PBS and 0.05% BSA with 0.05% Sodium Azide | |
Apoptosis regulator Bcl-X, bcl2-L-1, BCL2-like 1, bcl-2-like protein 1, BCLXBCL2LBcl-X, bcl-xL, BCLXL, BCL-XL/S, bcl-xS, BCLXS, DKFZp781P2092 | |
Mouse | |
27 kDa | |
0.02 mg | |
Apoptosis, Cancer, Tumor Suppressors | |
598 | |
Human, Mouse, Rat, Pig | |
Purified |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction